S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LQDA

Liquidia (LQDA) Stock Price, News & Analysis

$14.75
-0.32 (-2.12%)
(As of 03/28/2024 ET)
Today's Range
$14.63
$15.12
50-Day Range
$11.97
$16.73
52-Week Range
$5.71
$16.99
Volume
1.98 million shs
Average Volume
987,260 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Liquidia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
42.4% Upside
$21.00 Price Target
Short Interest
Bearish
9.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Liquidia in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$862,904 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.01) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.31 out of 5 stars

Medical Sector

563rd out of 938 stocks

Pharmaceutical Preparations Industry

254th out of 423 stocks

LQDA stock logo

About Liquidia Stock (NASDAQ:LQDA)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

LQDA Stock Price History

LQDA Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Liquidia (NASDAQ:LQDA) Hits New 52-Week High at $16.74
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
LQDA Apr 2024 7.500 call
Liquidia Full Year 2023 Earnings: Misses Expectations
Unveiling 6 Analyst Insights On Liquidia
What Wall Street expects from Liquidia Technologies's earnings
Liquidia Stock (NASDAQ:LQDA), Short Interest Report
See More Headlines
Receive LQDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LQDA
Fax
N/A
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$32.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+42.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-78,500,000.00
Net Margins
-448.89%
Pretax Margin
-448.89%

Debt

Sales & Book Value

Annual Sales
$17.49 million
Book Value
$0.73 per share

Miscellaneous

Free Float
52,003,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
0.14
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Roger A. Jeffs Ph.D. (Age 62)
    CEO & Director
    Comp: $532.23k
  • Mr. Michael Kaseta (Age 47)
    COO & CFO
    Comp: $627.85k
  • Mr. Russell SchundlerMr. Russell Schundler (Age 49)
    General Counsel & Corporate Secretary
    Comp: $541.92k
  • Mr. William R. Kenan Jr.
    Co-Founder
  • Dr. Ginger Denison
    Co-Founder
  • Jennifer Almond
    Director of Investor Relations & Corporate Communications
  • Ms. Sarah Krepp SPHR
    Vice President of People & Culture
  • Mr. Jason Adair (Age 50)
    Chief Business Officer
  • Dr. Tushar Shah M.D. (Age 63)
    Senior Vice President of Product Development
    Comp: $792.36k
  • Mr. Scott Moomaw (Age 53)
    Chief Commercial Officer

LQDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Liquidia stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LQDA shares.
View LQDA analyst ratings
or view top-rated stocks.

What is Liquidia's stock price target for 2024?

5 Wall Street analysts have issued 1 year price objectives for Liquidia's shares. Their LQDA share price targets range from $3.00 to $32.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price.
View analysts price targets for LQDA
or view top-rated stocks among Wall Street analysts.

How have LQDA shares performed in 2024?

Liquidia's stock was trading at $12.03 at the start of the year. Since then, LQDA shares have increased by 22.6% and is now trading at $14.75.
View the best growth stocks for 2024 here
.

When is Liquidia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LQDA earnings forecast
.

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The firm had revenue of $3.18 million for the quarter, compared to analysts' expectations of $2.48 million. Liquidia had a negative trailing twelve-month return on equity of 132.16% and a negative net margin of 448.89%.

What ETF holds Liquidia's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 13,817 shares of LQDA stock, representing 0.92% of its portfolio.

What other stocks do shareholders of Liquidia own?
When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia's major shareholders?

Liquidia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.38%), Vanguard Group Inc. (4.38%), Kynam Capital Management LP (4.16%), Findell Capital Management LLC (3.21%), Vestal Point Capital LP (1.58%) and Opaleye Management Inc. (0.69%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Jason Adair, Michael Kaseta, Paul B Manning, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw.
View institutional ownership trends
.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LQDA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners